[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

2024 American College of Cardiology’s Expert Consensus Decision Pathway for Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF), the most recent international guidance on HFrEF treatment, recommends angiotensin receptor/neprilysin inhibitor (ARNI; ie, sacubitril/valsartan) as the preferred renin-angiotensin system inhibitor (RASI), which should be used as first-line therapy whenever possible. Emphasis is placed on initiating and titrating guideline-directed medical therapy (GDMT) early and rapidly. Here is why and how.